(Q37957770)

25 August 2017

Targeting treatment-resistant depression (English)

1 reference

25 August 2017

Monica Mathys

1

1 reference

PubMed ID

22095575

25 August 2017

Brian G Mitchell

series ordinal

2

1 reference

25 August 2017

17 November 2011

1 reference

Journal of Pharmacy Practice

25 August 2017

1 reference

25 August 2017

24

1 reference

25 August 2017

6

1 reference

25 August 2017

520-533

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

25 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study. Functional status, health service use and treatment of people with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

The prognosis of depression in old age: outcome six to eight years after clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

The impact of medical comorbidity on acute treatment in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Report by the ACNP Task Force on response and remission in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Risperidone for treatment-refractory major depressive disorder: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

T3 augmentation of SSRI resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Folate and unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Enhancement of recovery from psychiatric illness by methylfolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

S-adenosyl methionine (SAMe) augmentation in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Clinical and biological effects of mifepristone treatment for psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Combined pharmacotherapy and psychological treatment for depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Efficacy of ECT in depression: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Light therapy for seasonal affective disorder. A review of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Controlled trial of bright light for nonseasonal major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Clinical and chronobiological effects of light therapy on nonseasonal affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011426972

21 January 2018

Identifiers

DOI

10.1177/0897190011426972

1 reference

25 August 2017

1 reference

PubMed ID

22095575